Atrium Therapeutics Inc RNA

Morningstar Rating
$6.68 +0.20 (3.09%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RNA is trading at a LOCK|&sRJw premium.
Price
$6.48
Fair Value
LOCK|.FX@^%&#
Uncertainty
LOCK|vH z<cpr
1-Star Price
LOCK|.?M&m!rR
5-Star Price
LOCK|rgc%^<
Economic Moat
LOCK|TG
Capital Allocation
—

News

Trading Information

Previous Close Price
$6.48
Day Range
$6.47–6.78
52-Week Range
$6.38–16.57
Bid/Ask
$6.69 / $6.72
Shares Outstanding
21.57M
Market Cap
$144.42M
Volume/Avg
117,008 / 293,101

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.85
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
—
Website
—

Valuation

Metric
RNA
Price/Earnings (Normalized)
—
Price/Book Value
0.52
Price/Sales
2.85
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
RNA
Quick Ratio
10.02
Current Ratio
10.46
Interest Coverage
—
Quick Ratio
RNA

Profitability

Metric
RNA
Return on Assets (Normalized)
−30.20%
Return on Equity (Normalized)
−39.16%
Return on Invested Capital (Normalized)
−38.69%
Return on Assets
RNA

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$>gBhVCLOCK|W%Wv$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|YNl!LW?LOCK|d>ynG$99B
Moderna Inc
MRNA
LOCK|^!$p$&LOCK|?t$84B
argenx SE ADR
ARGX
LOCK|%RHyl^LOCK|<@$59B
BeOne Medicines Ltd ADR
ONC
LOCK|H$$xLwcLOCK|!RM$48B
Royalty Pharma PLC Class A
RPRX
LOCK|tV^^?PkLOCK|H&Wm$$31B
Incyte Corp
INCY
LOCK|B<r&@%LOCK|&#$24B
BioNTech SE ADR
BNTX
LOCK|B$CGv&&LOCK|%qP$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|%@>lg$$LOCK|tgrr#$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|&^P$SSvLOCK|Qn$15B

Sponsor Center